Welcome to our dedicated page for XORTX Therapeutics SEC filings (Ticker: XRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XORTX Therapeutics Inc. filings document foreign issuer reports for a clinical-stage pharmaceutical company developing therapies for gout and progressive kidney disease. The records describe its XRx-026, XRx-008, XRx-101, XRx-225 and VB4-P5 programs, including disease focus, development stage and acquired intellectual property, regulatory documentation and manufacturing data for the VB4-P5 kidney anti-fibrotic asset.
The company’s Form 6-K disclosures also cover capital structure and exchange-listing matters, including a completed share consolidation, Nasdaq continued-listing compliance, preliminary stockholders’ equity information, acquisition consideration involving common shares and pre-funded warrants, and shareholder meeting results. Governance filings report director elections, auditor appointments, stock option plan approval and related voting outcomes.
XORTX Therapeutics Inc. is calling an annual and special shareholder meeting on March 24, 2026 to vote on several key corporate items. Shareholders will elect five directors, reappoint Davidson & Company LLP as auditor, and re-approve a rolling stock option plan reserving up to 10% of outstanding common shares for equity incentives.
The company is also asking shareholders to authorize a share consolidation of up to five pre‑consolidation shares for one post‑consolidation share. This flexibility is intended to help XORTX regain compliance with Nasdaq’s US$1.00 minimum bid price requirement before an April 13, 2026 deadline, after which its shares risk delisting if compliance is not restored. As of February 20, 2026, XORTX had 6,962,218 common shares outstanding.
XORTX Therapeutics filed its 2025 audited financial statements and MD&A, showing a net loss of $2,656,304 and negative operating cash flow of $2,768,723. Cash fell to $864,514 at December 31, 2025, with an accumulated deficit of $23,824,557 and shareholders’ equity of $2,084,459.
The auditors and management highlight a material uncertainty that casts significant doubt on XORTX’s ability to continue as a going concern because it must secure additional financing to fund research, clinical trials and operations. In 2025 the company raised equity, issued and exercised pre‑funded warrants, and expanded its warrant structure to fund activities.
XORTX signed a binding term sheet to acquire the VB4‑P5 renal anti‑fibrotic program from Vectus Biosystems for $3,000,000 in shares and recorded $293,803 of deferred acquisition costs. The company also discloses a Nasdaq notice of non‑compliance with minimum bid price rules while working to regain compliance.
XORTX Therapeutics Inc. has filed Amendment No. 1 to a Form F-1 to register a primary offering of up to 12,500,000 common shares, 12,500,000 pre-funded warrants, 12,500,000 common warrants and 25,000,000 common shares issuable upon warrant exercises. The securities are offered on a reasonable best efforts basis at an assumed price of $0.40 per share, the recent Nasdaq closing price. Each share or pre-funded warrant is sold together with one common warrant, which will be exercisable for three years at a price no lower than the latest TSXV closing price. XORTX estimates net proceeds of about $4.3 million, intended mainly to fund research and development, working capital and general corporate purposes. The company highlights its late-stage gout program XRx-026, ADPKD program XRx-008, and additional kidney and metabolic disease candidates, while cautioning that investing in the securities involves a high degree of risk and potential dilution.
XORTX Therapeutics Inc. filed a Form 6-K highlighting more time to close its planned acquisition of Vectus Biosystems’ Renal Anti-Fibrotic Therapeutic Program, including the novel compound VB4-P5. An amendment now targets closing on or before March 31, 2026 to complete intellectual property transfer and final documentation.
The company also scheduled its Annual and Special Meeting of Shareholders for March 24, 2026, with shareholders of record on February 20, 2026 eligible to vote. In connection with appointing Krysta Davies Foss to the board, XORTX granted 20,000 stock options at an exercise price of CAD $0.69 for five years.
XORTX Therapeutics Inc. filed a Form 6-K. The filing incorporates Exhibits 99.2 and 99.3 by reference into the company’s Registration Statement on Form F-3 (File No. 333-269429), adding legal opinions regarding the legality of securities being registered from Dentons Canada LLP and Troutman Pepper Locke LLP.
The exhibit index also lists a press release dated October 29, 2025 (Exhibit 99.1). The report is signed by President and Chief Executive Officer Allen Davidoff on October 31, 2025. This is an administrative update linking legal opinions to the existing F-3 shelf.
XORTX Therapeutics Inc. filed a Form 6-K furnishing transaction-related exhibits and incorporating them by reference into its Form F-3 registration statement (File No. 333-269429), as amended and supplemented.
The exhibits include a press release dated October 21, 2025, a Placement Agency Agreement with D. Boral Capital LLC, a form of Securities Purchase Agreement, a form of Lock-Up Agreement, and a form of Pre-Funded Common Share Purchase Warrant. The report was signed by President and CEO Allen Davidoff on October 22, 2025.
XORTX Therapeutics Inc. launched a registered direct offering to an institutional accredited investor, registering 572,470 common shares at $0.63 each, 1,177,530 pre-funded warrants at $0.62999 each with a $0.00001 exercise price, and 1,177,530 common shares underlying those warrants. The pre-funded warrants are immediately exercisable.
The fee table shows an aggregate offering price of $1,102,488, placement agent fees of $77,175, and proceeds before expenses of $1,025,313. The company estimates net proceeds of approximately $0.8 million for working capital and general corporate purposes. A beneficial ownership cap limits exercises above 4.99% (or, at the purchaser’s election at closing, 9.99%).
XRTX trades on the TSXV and Nasdaq. The company has applied to list the Shares and the Pre-Funded Warrant Shares on the TSXV and notified Nasdaq; TSXV approval is required. D. Boral Capital LLC is acting as exclusive placement agent on a best efforts basis. Delivery is expected on or about October 23, 2025, subject to customary conditions and TSXV approvals.